NovoCure LimitedNVCRNASDAQ
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +21.81% | +20.54% | +11.91% | +5.62% | +7.81% |
| Gross Profit Growth | +25.72% | +26.25% | +11.12% | +1.41% | +2.30% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +1.38% | +0.79% | +2.81% | +3.59% | +3.38% |
| Weighted Average Shares Diluted Growth | +1.38% | +0.79% | +2.81% | +3.59% | +3.38% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +98.28% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | -24.05% | +32.37% | +82.13% | +99.46% | +27.10% |
| Inventory Growth | +6.22% | -8.04% | -6.90% | -0.57% | -100.00% |
| Asset Growth | +6.60% | +8.26% | +11.36% | +2.78% | +11.39% |
| Book Value per Share Growth | -9.61% | -1.42% | -2.03% | -6.75% | -8.48% |
| Debt Growth | +14.51% | +14.61% | +17.05% | +3.71% | +18.10% |
| R&D Expense Growth | -3.25% | -5.70% | +4.22% | +1.60% | +4.14% |
| SG&A Expenses Growth | +0.08% | +41.83% | +6.15% | +7.07% | +4.54% |